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Dravet syndrome (DS),  or severe myoclonic epilepsy in infancy,  is one of the most severe types of 
genetic epilepsy.  It is characterized by the initial occurrence of febrile or afebrile seizures that often 
evolve into status epilepticus in infants with normal development,  and by the subsequent appearance 
of myoclonic and/or atypical absence seizures as well as complex partial seizures.  The key feature 
that characterizes DS is fever sensitivity,  although photosensitivity and pattern-sensitivity are also 
often seen.  The prognosis is unfavorable in most cases.  Seizures become drug-resistant and persist,  
with many patients suﬀering from motor and cognitive impairment.  Mutations of SCN1A,  which 
encodes the voltage-gated sodium channel NaV1.1,  are the most frequent genetic cause of this syn-
drome.  SCN1A mutations and/or microchromosomal rearrangements involving SCN1A are detected 
in about 85ｵ of patients.  Mutations of PCDH19 have also been reported in female patients with 
clinical ﬁndings compatible with DS.  PCDH19 mutations might account for 5ｵ of overall DS cases.  
Thirty years after its ﬁrst description,  DS is considered as a model of channelopathy.  This survey 
reviews recent developments in the research literature on DS,  focusing on the clinical course,  as well 
as its genetic causes.
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ravet syndrome (DS) is a rare form of child-
hood-onset epilepsy with a genetic etiology.  DS 
was originally named “severe myoclonic epilepsy in 
infancy” [1,  2],  and is characterized by a variety of 
treatment-resistant seizures and a poor cognitive 
prognosis.  DS is considered to be a form of epileptic 
encephalopathy,  in which the epileptic activity itself 
may contribute to severe cognitive and behavioral 
impairments [3].
　 DS is a representative type of channelopathy which 
is,  in most cases,  caused by mutation of genes encod-
ing ion channels [4].  In this survey of the recent lit-
erature,  the most signiﬁcant ﬁndings are summarized 
to promote greater understanding of the clinical 
course and pathogenesis of DS.
Clinical and Electroencephalographic  
Aspects of DS
　 Onset of epilepsy. The onset of seizures in DS 
occurs during the ﬁrst year of life,  with a mean age of 
5-8 months.  DS patients usually have no pathological 
history or developmental delay before the onset of 
seizures [5].
　 The ﬁrst seizure is typically a clonic,  generalized 
or unilateral,  convulsive seizure.  Seizures are often 
triggered by fever.  Afebrile seizures,  focal seizures,  
and complex partial seizures can also occur.  These 
seizures,  with or without fever,  tend to last for more 
than 20min,  and evolve into status epilepticus.
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　 At onset,  the electroencephalogram (EEG) is usu-
ally normal for infants at this age,  with only rare,  if 
any,  epileptic discharges [2].
　 Evolution of epilepsy. Patients with typical 
DS have multiple seizure types during the course of 
the disease [2].
　 Convulsive seizures,  including generalized tonic-
clonic seizures (GTCS),  generalized clonic seizures 
(GCS),  and alternating unilateral clonic seizures,  are 
the main seizure types occurring throughout life in 
most patients.  These convulsive seizures may be pro-
longed or repeated,  developing into status epilepticus 
that lasts longer than 30min and requires intravenous 
antiepileptic drug administration.  The frequency of 
convulsive status epilepticus in the ﬁrst year of life is 
very high,  and then decreases gradually [6,  7].
　 Myoclonic seizures appear at the ages of 1-5 
years,  with an average of around 2 years.  The symp-
toms can be either massive or segmental,  and are 
often observed in clusters - particularly before convul-
sive seizures.  Myoclonus observed in DS patients can 
be divided into 2 groups,  epileptic myoclonic seizures 
and non-epileptic myoclonia.  The former is concomi-
tant with paroxysmal discharges (mainly with general-
ized spike and wave complexes) on the EEG,  whereas 
the latter does not have an EEG correlate.  Both types 
can occur during the clinical disease course,  and it is 
often diﬃcult to distinguish the former from the latter 
without precise analyses using video-EEG-EMG simul-
taneous monitoring [5].
　 There are some patients with clinical characteris-
tics similar to those of “typical” DS but lacking epi-
leptic myoclonic seizures and atypical absence sei-
zures,  although appearance of these seizure types is 
a unique feature of DS.  These patients have been 
deﬁned as having “borderline” DS by some research-
ers [8,  9].  Myoclonic seizures and atypical absence 
seizures tend to disappear during the course in typical 
DS patients,  and it becomes diﬃcult to distinguish 
typical DS from borderline DS from adolescence 
onward.  Several long-term studies [2,  7] have shown 
that patients with typical DS and those with border-
line DS experience fundamentally similar late clinical 
courses,  including seizure frequencies and mental 
prognoses.  In addition,  both types have high rates of 
SCN1A mutations [10,  11,  12],  which led to the 
perception that the spectrum of typical and borderline 
DS cases constitutes a single syndromic entity.
　 Atypical absence seizures can appear either at 1-3 
years,  together with myoclonic seizures,  or later on,  
at 5-12 years of age.  The symptoms can be divided 
into atypical absence seizures characterized by unre-
sponsiveness,  or may include an additional myoclonic 
component.  This seizure type corresponds to several 
seconds of bursts of generalized,  irregular spike and 
wave complexes in EEG [5].
　 Obtundation status is a type of nonconvulsive status 
epilepticus that consists of an impairment of con-
sciousness of variable intensity with fragmentary and 
segmental,  erratic myoclonia involving the limbs and 
face.  Sometimes it is associated with drooling and a 
slight increase of muscle tone.  Convulsive seizures 
can either occur at the onset,  during,  or at the end of 
obtundation status.  These periods can be prolonged 
for several hours,  or even days.  EEGs usually show 
diﬀusely slow background,  intermingled with focal and 
diﬀuse epileptic discharges [13].
　 Simple partial seizures or complex partial seizures 
also occur in many patients.  They can appear as early 
as 4 months up until the age of 4 years.
　 DS seizure onset is characterized by very severe 
sensitivity to fevers.  In addition to high fevers,  sei-
zures can also be induced by subtle elevation of body 
temperature caused by the very beginning stage of 
infection,  hot bath immersion,  exercise,  and hot 
weather [14].
　 Photosensitivity can be manifested as a pathologi-
cal response to intermittent photic stimulation,  bright 
light,  or intense contrast between bright light and 
darkness.  All kinds of contrasting patterns,  such as 
geometrical designs or dotted lines,  can provoke sei-
zures [15,  16].
　 The EEG background often becomes progressively 
slower and more poorly organized.  The peculiar theta 
activity in fronto-central areas that is already observed 
at onset in some patients,  appears in most cases,  and 
persists throughout follow-up.  Epileptic discharges 
are represented by spikes,  spike and wave complexes,  
and poly spike-waves [13,  16].
　 Long-term outcomes. DS was originally believed 
to be always associated with unfavorable outcomes.  
All patients were reported to have persistent seizures 
and to be cognitively impaired,  often severely.  Several 
authors have published longitudinal studies following 
a series of patients through to adolescence,  but only a 
few series included patients older than 20 years [7,  
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17-20].
　 All seizure types are extremely resistant to any 
kind of treatment during the ﬁrst several years.  Later 
on,  partial seizures,  myoclonic seizures and atypical 
absences tend to disappear but convulsive seizures 
persist.  However,  in 2 very long-term studies,  seven 
patients were reported to have become seizure-free 
for at least 1 year and up to 5 years [7,  18].  In our 
series,  5 out of 31 patients (16.1ｵ) were seizure-
free in adulthood.  The seizure-free patients had 
experienced signiﬁcantly fewer episodes of convulsive 
status epilepticus.  Prevention of the occurrence of 
convulsive status epilepticus might improve seizure 
prognosis in DS [7,  21].
　 In the remaining patients,  the frequency of convul-
sive seizures gradually decreased,  despite recurrent 
periods of worsening during adolescence and early 
adulthood in some patients.  At the end of the follow-
up,  the frequency of seizures was reported to range 
from 1-12 per year [18].
　 The convulsive seizures in adult DS have not been 
fully clariﬁed.  Some researchers describe them as 
tonic-clonic seizures without providing detailed infor-
mation,  whereas others report focal features [2,  6,  
22].  In our study,  35 (87.5ｵ) of the 40 apparently 
generalized convulsive seizures were demonstrated to 
actually be partial seizures,  mostly having a frontal 
origin,  with or without secondary generalization in the 
ictal EEG records [7].
　 Convulsive status epilepticus was no longer 
observed in most adult patients,  although it still 
occurred in adulthood in only a few patients.  
Obtundation status remained in most severely aﬀected 
patients [19].  Fever and infections were triggering 
factors for only one-third to half of the cases in adult-
hood.  Photosensitivity and pattern sensitivity disap-
peared in most patients [7,  18].
　 Interictal epileptic EEG abnormalities can disap-
pear completely or become sporadic.  They are char-
acterized by focal and multifocal spikes,  spike-waves 
and sharp waves,  and are only rarely associated with 
generalized spike-waves.  Photosensitivity becomes 
progressively less apparent.  Nevertheless it persists 
in some cases and was observed in 12ｵ of patients 
older than 18 years in one series [13].
　 It is generally believed that almost all patients with 
DS show severe mental deﬁcits [12,  16],  although 
recently published long-term studies showed that some 
patients had only moderate to minimum mental dis-
ability in adulthood.  Among these patients,  only a 
small number could live independent lives.  In our 
series,  a lack of occipital alpha rhythms on follow-up 
EEGs was signiﬁcantly correlated with severe mental 
handicaps in adulthood,  and it is thought that a slow 
EEG background must represent brain dysfunction.  
To improve the mental prognosis of DS,  suppression 
of seizures might have a positive eﬀect,  especially 
when seizure control is achieved at a young age,  
although this may not be enough to exert a signiﬁcant 
eﬀect [7].
Review of the Genetic Aspects of DS (Table 1)
　 Sodium channel α1 subunit gene (SCN1A) 
and Dravet syndrome. Mutations of SCN1A are 
the most frequent genetic cause of DS.  At present,  
more than 700 mutations have been associated with DS 
and are randomly distributed along the gene [23-25].  
SCN1A (on chromosome 2q24.3) encodes the voltage-
gated sodium channel NaV1.1.  Voltage-gated sodium 
channels (VGSCs) play an essential role in neuronal 
excitability.
　 Mutations of SCN1A were ﬁrst discovered in the 
syndrome of generalized epilepsy with febrile seizures 
plus (GEFS＋) [26],  which has been renamed “genetic 
epilepsy with febrile seizures plus” [27].  A family 
history of epilepsy or febrile seizures is sometimes 
found in patients with DS and most aﬀected relatives 
have GEFS＋ phenotypes [28].  In view of the predis-
position to seizures with fever that typically occurs in 
Dravet syndrome,  Claes et al.  performed a mutation 
analysis on SCN1A in 7 children and found that all had 
de novo mutations [4].
　 Functional eﬀects of voltage-gated sodium 
channel α1 mutations. Most mutations respon-
sible for DS are either missense or truncation muta-
tions,  both of which would give rise to nonfunctional 
channels.
　 Epilepsy is a disorder characterized by brain 
hyperexcitability and it initially seemed puzzling that 
mutations in a VGSC lead to loss of function and 
reduced Na＋ current.  However,  data from Scn1a 
knock-out mice [29] and knock-in mice with a nonsense 
mutation in the Scn1a gene [30] have shown that the 
α1 subunit is fundamental for the excitability of at 
least some types of γ-aminobutyric acid (GABA)-ergic 
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interneurons in the neocortex and hippocampus.  
Therefore,  reduced ﬁring of inhibitory neurons and 
compromised network inhibition could be the major 
pathophysiologic mechanism causing SCN1A-related 
genetic epilepsies.
　 Detection of SCN1A mutations. The overall 
frequency of SCN1A alterations in DS,  which includes 
sequence-based mutations,  single or multiple exon 
deletions,  and chromosomal rearrangements,  is around 
85ｵ.  By classical Sanger sequencing,  mutations are 
found in about 80ｵ of cases and comprise truncating 
(40ｵ) and missense (40ｵ) mutations,  with the remain-
ing alterations being splice site changes [31].
　 Patients with a clinical diagnosis of DS who test 
negative for SCN1A mutations after sequencing may 
still have exonic deletions or chromosomal rearrange-
ments involving SCN1A [23,  24,  32-34].  The size of 
these genomic alterations varies from the megabase 
range,  involving a large number of contiguous genes,  
down to one exon within SCN1A.  Duplications and 
ampliﬁcations involving SCN1A can be identiﬁed with 
multiplex ligation-dependent probe amplification 
(MPLA) and further characterized by comparative 
genome hybridization (CGH) to determine the size of 
the abnormality and identify any additional genes 
involved.  Intragenic and whole-gene deletions includ-
ing SCN1A and/or contiguous genes account for 2-3ｵ 
of Dravet syndrome cases and for about 12.5ｵ of 
those who are mutation-negative on classical Sanger 
sequencing [35].
　 Mode of inheritance. Most mutations are de 
novo,  comprising both truncating and missense changes.  
However,  familial mutations also occur in 5-10ｵ of 
cases and are usually missense in nature [4,  10,  36,  
37].  In these cases,  other family members with the 
SCN1A mutation have no symptoms or mild pheno-
types consistent with the GEFS+ spectrum [10,  36].
　 An important genetic counseling issue is that sev-
eral families with more than one child with DS have 
been recorded.  Somatic or germline mosaic mutations 
might explain the presence of an unaﬀected or mildly-
aﬀected transmitting parent [38-41].  A recent study 
indicates that mosaicism is found in at least 7ｵ of 
families with DS.  The proportion of the mutated 
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Table 1　 Genetic background of Dravet syndrome
Gene (location) Product
Proportion of
cases in Dravet
syndrome
Contribution References
SCN1A (2q24) Voltage-gated
sodium channel α1
subunit
Around 85% Typical and
borderline
Dravet syndrome
Claes et al. [4]
Depienne et al. [25]
PCDH19  (Xq22) Protocadherin 19 Around 5% Mild type of
Dravet syndrome
Depienne et al. [51]
GABRG2  (5q34) GABAA receptor γ2
subunit
Rare Not yet
established
Harkin et al. [53]
SCN1B (19q13) Voltage-gated
sodium channel β1
subunit
Rare Not yet
established
Patino et al. [54]
SCN2A (2q24) Voltage-gated
sodium channel α2
subunit
Rare Not yet
established
Shi et al. [55]
SCN9A (2q24) Voltage-gated
sodium channel α9
subunit
Unknown Modiﬁer Singh et al. [47]
CACNB4  (2q22-q23) Voltage-dependent
calcium channel β4
subunit
Unknown Modiﬁer Ohmori et al. [48]
allele in the blood of the 12 patients described varied 
from 0.04ｵ to 85ｵ and may be a signiﬁcant factor 
underlying intrafamilial phenotypic variability [39,  
42,  43].
　 Genotype-phenotype correlations. Some gen-
eral genotype‒phenotype correlations have been 
suggested: truncating,  nonsense,  frame shift muta-
tions,  and partial or whole-gene deletions are corre-
lated with a classical DS phenotype and appear to 
have a signiﬁcant correlation with an earlier age of 
seizure onset [24].
　 The severity of the phenotypes may also be corre-
lated with the location of SCN1A missense mutations:  
for example,  those in the pore-forming region of the 
sodium channel may cause DS,  whereas missense 
changes associated with the GEFS＋ spectrum may be 
more frequently located outside the pore-forming 
region [44].  However,  this genotype-phenotype cor-
relation is not consistent.  Moreover,  the same SCN1A 
mutations and deletions cause DS in some patients and 
GEFS＋ in others [26,  45,  46],  suggesting that 
modiﬁer genes,  the genetic background,  and/or envi-
ronmental factors may also play a role in some 
patients,  and thus DS may sometimes follow a com-
plex model of inheritance.  SCN9A or CACNB4 muta-
tions,  along with SCN1A mutations,  have been 
reported as candidates for modiﬁer genes in DS 
patients [47,  48].
Dravet Syndrome without SCN1A Alterations
　 PCDH19. Mutations of PCDH19 (on chromo-
some Xq22),  the gene encoding protocadherin 19,  
have been found in a disorder called “epilepsy limited 
to females with mental retardation” (EFMR) [49,  
50].  EFMR is a disorder with an unusual X-linked 
inheritance pattern,  where the disorder is expressed 
in heterozygous females,  and hemizygous males are 
unaﬀected carriers.
　 Depienne et al.  [51] reported PCDH19 familial and 
de novo point mutations in 13 female patients with 
clinical ﬁndings compatible with DS.  A male patient 
with a similar phenotype carried a mosaic PCDH19 
mutation.  The authors estimated that 16ｵ of their 
SCN1A-negative DS patients had PCDH19 mutations 
and that this gene might account for 5ｵ of DS cases 
overall.  The biologic role of PCDH19 is unknown;  
this gene is expressed in the developing brains of 
humans and mice,  and is postulated to be involved in 
establishing neuronal connections and signal transduc-
tion at the synaptic membrane [52].
　 Possible causative genes of DS. The etiol-
ogy of DS in about 10ｵ to 20ｵ of patients remains 
unknown,  and additional genes are likely to be impli-
cated.  Among these patients,  only a few cases with 
mutation of other genes (GABRG2,  SCN1B,  and 
SCN2A genes) have been reported [53-55].
SCN1A Mutations Associated with Other 
Forms of Epilepsy
　 The second most common phenotypes among 
SCN1A-related epilepsies are febrile seizures and 
related syndromes [56].  The remaining associated 
epileptic conditions comprise a heterogeneous group of 
cryptogenic focal and cryptogenic generalized epilepsy,  
as well as infrequent occurrences of myoclonic astatic 
epilepsy [57,  58],  severe idiopathic generalized epi-
lepsy of infancy [58],  West syndrome [37],  Lennox-
Gastaut syndrome [57],  and Rasmussen encephalitis 
[59].
Conclusion
　 It has been more than 30 years since the ﬁrst 
description of DS,  and the syndrome is now consid-
ered a model for channelopathy and is the subject of 
wide interest in the scientiﬁc and medical community.  
DS is one of the most severe types of genetic epilepsy,  
and we need further studies to understand its patho-
genesis and the mechanisms by which it causes cogni-
tive impairments.  Finally,  further study is needed to 
improve the care and treatment of aﬄicted patients.
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